Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Respir Crit Care Med. 2007 Dec;28(6):596-603.

Optimizing use of aminoglycosides in the critically ill.

Author information

  • 1Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA. rhonda_rea@yahoo.com

Abstract

In the era of increasing bacterial resistance and a lack of development of new antimicrobials for the treatment of gram-negative infections, aminoglycosides (AGs) are more commonly used in combination with other antimicrobials for the treatment of life-threatening infections in the intensive care unit (ICU). AGs display concentration-dependent killing activity; thus the rate and extent of bacterial killing increase with increasing peak (Cmax) drug concentrations. Optimizing AG dosing requires attainment of a pharmacodynamic target ratio (Cmax:minimal inhibitory concentration [MIC] > or = 10) upon first dose, which is associated with a more rapid rate of resolution of infection. Extended-interval AG dosing has been shown to attain this target in the general patient population while decreasing the risk of nephrotoxicity compared with multiple daily dosing. However, ICU patients have pharmacokinetic differences compared with patients who are less ill, including increased volume of distribution and variable clearance, which may make attainment of this target difficult. The need for extended-interval aminoglycoside dosing with Cmax monitoring and MIC determination of the pathogen may be needed to optimally treat serious infections in the critically ill.

PMID:
18095223
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Write to the Help Desk